Voyager reports Q3 2026 results, cash runway into Q2 2028
The company said VY7523 tau PET data remain on track for Q4 2026 and VY1706 dosing should begin within months, pending enrollment.
Voyager Therapeutics reported third quarter 2026 financial and operating results on November 5, 2026, in Lexington, Massachusetts.
CEO Alfred W. Sandrock, Jr. said the company expects to report PET imaging data from its VY7523 multiple ascending dose trial in the fourth quarter and to dose the first patient with its lead gene therapy VY1706 in the next few months.1 For VY7523, an anti-tau antibody, the last patient visit is complete, and Voyager continues to expect tau PET imaging efficacy data in Q4 2026 from the multiple ascending dose trial in participants with Alzheimer's disease.1
For VY1706, a tau silencing gene therapy, patient screening continues in the United States for the clinical trial in adults with early Alzheimer's disease. Pending enrollment, the company anticipates dosing could start within a few months, with initial acute safety data expected in the first quarter of 2027, and possible capsid platform validation data from cerebrospinal fluid tau biomarkers roughly a year after dosing begins.1
On the Friedreich's ataxia program, NBIB-'223, Voyager's partner Neurocrine Biosciences said the program is on track to begin a Phase 1 study within the coming months, with initial patient-level data expected in 2027.1
Financially, collaboration revenue was $4.0 million for the third quarter of 2026, compared to $13.4 million for the third quarter of 2025.1 Research and development spending declined to $24.4 million from $35.9 million a year earlier, which the company attributed to lower clinical and manufacturing costs and program prioritization, per research and development expenses were $24.4 million for the third quarter of 2026, compared to $35.9 million for the third quarter of 2025, primarily due to lower clinical and manufacturing costs and program prioritization.1
Net loss was $24.7 million for the quarter, versus $27.9 million a year earlier, with cash, cash equivalents, and marketable securities of $132.1 million as of September 30, 2026.1 Voyager said this is expected to fund planned operations into the second quarter of 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.